Completed dosing of the first three patients at the 3E13 vg/kg dose (Cohort 1) in MyPEAK-1 clinical trial with no unexpected events or toxicities associated with study drug observed.

Implemented changes to the MyPEAK-1 protocol intended to support future development, including adding a baseline biopsy; expanding trial participant eligibility to include obstructive HCM patients and patients without implantable cardioverter defibrillators (ICDs).

TN-201 was granted rare pediatric disease designation by the U.S. Food and Drug Administration for the treatment of MYBPC3-associated HCM in individuals under the age of 18.

Entered into a $45 million credit facility with Silicon Valley Bank (SVB) in August 2024.